Americas Gastrointestinal Drugs Market is Expected to Reach 59.3 billion by 2023 at CARG of 6% during Forecast Period of 2017-2023

About This Presentation
Title:

Americas Gastrointestinal Drugs Market is Expected to Reach 59.3 billion by 2023 at CARG of 6% during Forecast Period of 2017-2023

Description:

Gastrointestinal (GI) drug market involves pharmacological and non-pharmacological treatment. Different types of gastrointestinal disorder includes constipation, diverticular diseases, colon polyps, irritable bowel syndrome, and many more. – PowerPoint PPT presentation

Number of Views:2

less

Transcript and Presenter's Notes

Title: Americas Gastrointestinal Drugs Market is Expected to Reach 59.3 billion by 2023 at CARG of 6% during Forecast Period of 2017-2023


1
Americas Gastrointestinal Drugs Market is
Expected to Reach 59.3 billion by 2023 at CARG of
6 during Forecast Period of 2017-2023
SAMPLE
FOR MORE INFO
2
Americas Gastrointestinal Drugs Market
Market Highlights Gastrointestinal (GI) drug
market involves pharmacological and
non-pharmacological treatment. Different types of
gastrointestinal disorder includes constipation,
diverticular diseases, colon polyps, irritable
bowel syndrome, and many more. Many of the GI
diseases can be prevented and minimized by
maintaining a healthy lifestyle and balanced
diet. The factors like increasing prevalence of
increasing of various different gastrointestinal
disease, increasing elderly population,
technological advances are responsible for
driving gastrointestinal market. Whereas
unavailability of treatment for some of gastro
intestinal diseases may be responsible for
hampering the market growth. Request For Sample
Report https//www.marketresearchfuture.com/sampl
e_request/583
3
Americas Gastrointestinal Drugs Market
AstraZeneca has entered into an agreement with
gastroenterology specialist Tillotts Pharma for
Entocort. Entocort is a gastroenterology medicine
for patients with mild to moderate Crohns
disease and ulcerative colitis. The medicine is
now available in across 40 countries, the product
sales gained 53 million outside the US in 2014.
The agreement shows that Tillotts will pay
AstraZeneca 215 million on completion of the
transaction to acquire the rights to sell and
develop Entocort capsules and formulations
outside the US. Janssen Biotech Inc., the
company received FDA approval for the Remicade
medicine which is used to treat pediatric
ulcerative colitis in 2011. Since then company
has a product for pediatric gasrtrointestinal
drugs. GlaxoSmithKline Plc, has a products Eno
available in Latin America and Asian market. The
product is doing extremely well in these regions.
The product is available in various flavor. The
product is an antacid. The product is also
available in different forms. Company has vast
range of products in consumers based and in
prescription based products. It hold very strong
presence worldwide.
4
Americas Gastrointestinal Drugs Market
Segmentation The Segmentation for Americas
Gastrointestinal Drug market is done on the basis
of drug category, route of administration,
disease type, and by end users. On the basis of
the drug category the market is segmented into
Acid Neutralizers, Laxatives Antidiarrheal,
Anti-inflammatory, Antiemetic and others. Further
the Acid Neutralizers are sub-segmented into
Antacid, H2 antagonists, Proton Pump Inhibitors
and others. On the basis of route of
administration the segments includes oral,
parental and rectal. On the basis of disease
type, market is segmented into gastro-esophageal
reflux diseases, inflammatory bowel diseases and
others. The inflammatory diseases are further
segmented into two types Crohns diseases and
ulcerative disease. The Ulcerative diseases are
further sub segmented into ulcerative protitis,
proctosigmoiditis, left sided colitis, pancolitis
and acute severe ulcerartive colitis. The end
user segment includes hospital pharmacies, retail
pharmacies and others. Ask for discount
https//www.marketresearchfuture.com/check-discoun
t/583
5
ABOUT US
MARKET RESEARCH FUTURE At Market Research Future
(MRFR), we enable our customers to unravel the
complexity of various industries through our
Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), Raw Research Reports
(3R), Continuous-Feed Research (CFR), and Market
Research Consulting Services. MRFR team have
supreme objective to provide the optimum quality
market research and intelligence services to our
clients. Our market research studies by products,
services, technologies, applications, end users,
and market players for global, regional, and
country level market segments, enable our clients
to see more, know more, and do more, which help
to answer all their most important questions. In
order to stay updated with technology and work
process of the industry, MRFR often plans
conducts meet with the industry experts and
industrial visits for its research analyst
members. For more information kindly visit
www.marketresearchfuture.com or contact us at
info_at_marketresearchfuture.com Copyright 2018
Market Research Future All Rights Reserved. This
document contains highly confidential information
and is the sole property of Market Research
Future. No part of it may be circulated, copied,
quoted, or otherwise reproduced without the
written approval of Market Research Future.
6
(No Transcript)
Write a Comment
User Comments (0)